Home
Resources
Follow portfolio news
...

Strategic alliance between Laboratoires Vivacy and Burgeon: aiming for excellence in skincare

Published on
15/4/2025
Amended on
23/3/2026
0
minute(s)
Odyssey 2022
Vivacy Laboratories
A French company participating in the Vintage FPCI Altaroc Odyssey 2022, Vivacy is reaching out to Burgeon, a Turkish biotechnology company. The alliance is intended to be transformative for the skin rejuvenation sector.
By
Antoine Orsoni
Antoine Orsoni
Strategic alliance between Laboratoires Vivacy and Burgeon: aiming for excellence in skincare
This article has been automatically translated. Please excuse any inaccuracies or translation errors.
Dieser Artikel wurde automatisch übersetzt. Bitte entschuldigen Sie etwaige Ungenauigkeiten oder Übersetzungsfehler.
Questo articolo è stato tradotto automaticamente. Ci scusiamo per eventuali inesattezze o errori di traduzione.

Vivacy has announced a strategic alliance with Burgeon Biotechnology, an innovative Turkish company based in Ankara, specializing in calcium hydroxyapatite-based biostimulators. This collaboration marks a significant step forward for Vivacy, which will be able to diversify its product range to include advanced skin regeneration solutions.

Burgeon is internationally renowned for its Novuma technology, a new-generation biostimulator designed to improve skin quality by stimulating collagen production. "This product responds directly to growing consumer demand for skin quality and skin rejuvenation. It perfectly complements our existing range of hyaluronic acid-based products. Stylinghyaluronic acid-based products, in which we hold a leading position in Europe", commented Bertrand Frohly, CEO of Vivacy.

By partnering with the Turkish company - present in over 45 countries - the French company gains access to complementary technology, and responds to growing consumer demand for treatments that promote skin quality and regeneration. Novuma is due to be rolled out in Europe over the coming months, with gradual expansion to other regions, consolidating Vivacy's international presence and affirming its commitment to innovation and excellence in the field of aesthetic medicine.

Founded in Paris in 2007, Vivacy is a pioneer in the development, production and distribution of premium hyaluronic acid-based medical devices dedicated to aesthetic and anti-aging medicine. Today, with 200 employees and a diversified geographical presence (80 countries), it is renowned for its Stylage range, produced using its patented technology.

Other episodes on this topic

Explore our content collections, which bring together different formats around a single subject/issue/theme.
No articles in this category yet.
No items found.
Europe
Healthcare
Welcome to Altaroc
To provide you with a tailored experience, we invite you to complete your profile.
Your profile
country of tax residence
Select
choosenCountry
Preferred language
Select
choosenLang
Your investor profile
Financial intermediary or Professional investor
Financial advisors, wealth management advisors, private bankers, or any other investment service providers.
Qualified Investor or Altaroc Investor
Experienced Investor or Altaroc Investor
Private investors who have already invested in Altaroc who have a minimum investment capacity of €100,000.
Private investors who have already invested in Altaroc who have a minimum investment capacity of €250,000.
Inexperienced investor
Individual investors with an investment capacity of less than €100,000.
Individual investors with an investment capacity of less than €250,000.
Institutional investor
Pension funds, retirement funds, asset management firms, and single-family offices.
Scroll down to accept General Terms and Conditions
The webpage you are trying to access is not available in your country.